Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: RemeGen Co., Ltd.
Condition: Non-Small Cell Lung Cancer
NCT06962865
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.